V

Vimian Group AB
STO:VIMIAN

Watchlist Manager
Vimian Group AB
STO:VIMIAN
Watchlist
Price: 38.25 SEK -3.89% Market Closed
Market Cap: 19.8B SEK
Have any thoughts about
Vimian Group AB?
Write Note

Net Margin
Vimian Group AB

0.1%
Current
4%
Average
2.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0.1%
=
Net Income
256k
/
Revenue
352.4m

Net Margin Across Competitors

Country SE
Market Cap 20.1B SEK
Net Margin
0%
Country JP
Market Cap 7.1T JPY
Net Margin
24%
Country CH
Market Cap 37.7B CHF
Net Margin
12%
Country DK
Market Cap 177.1B DKK
Net Margin
19%
Country US
Market Cap 16.1B USD
Net Margin
11%
Country KR
Market Cap 10.5T KRW
Net Margin
-358%
Country CN
Market Cap 51.1B CNY
Net Margin
42%
Country US
Market Cap 6.5B USD
Net Margin
29%
Country CA
Market Cap 6.4B USD
Net Margin
-8%
Country UK
Market Cap 4.6B GBP
Net Margin
7%
Country US
Market Cap 5.6B USD
Net Margin
9%
No Stocks Found

Vimian Group AB
Glance View

Market Cap
20B SEK
Industry
Health Care

Vimian Group AB is a relatively new player making waves in the veterinary and animal health industries. Founded in Sweden, Vimian is structured as a conglomerate composed of specialized subsidiaries focused on different niche markets within veterinary services, diagnostics, and technology. This strategic structure enables the company to operate across various segments such as Veterinary Services, Specialty Pharma, MedTech, and Diagnostics, achieving a holistic approach to animal healthcare. By acquiring and partnering with innovative companies globally, Vimian capitalizes on synergies and cross-market opportunities, ensuring a competitive edge in each of its operational fields. The company’s diverse portfolio allows it to cater not only to pet owners and veterinary professionals but also to livestock industries, ensuring comprehensive coverage in the growing market of animal welfare and health. Vimian’s revenue streams are multi-faceted, generated from a blend of product sales, subscriptions, and service fees. For instance, within its Specialty Pharma segment, the company develops and sells pharmaceutical products designed to treat common and specialty conditions in animals, thus generating continuous revenue from veterinary practices worldwide. In the MedTech segment, Vimian offers cutting-edge medical devices and equipment, enhancing veterinary surgical and diagnostic capabilities, which drives sales. Meanwhile, their Diagnostics division provides innovative testing solutions that help veterinarians identify and treat animal diseases accurately, offering another lucrative revenue stream. This multi-pronged business model not only mitigates risk through diversification but also positions Vimian as a key player in meeting the rapidly evolving demands of animal health and care.

VIMIAN Intrinsic Value
45.26 SEK
Undervaluation 15%
Intrinsic Value
Price
V
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0.1%
=
Net Income
256k
/
Revenue
352.4m
What is the Net Margin of Vimian Group AB?

Based on Vimian Group AB's most recent financial statements, the company has Net Margin of 0.1%.